Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Cardiovascular Disease, Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Interventions: Descemet membrane endothelial keratoplasty; Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 30 Years to 93 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 14
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 10 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cirrhosis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: High Risk for Postoperative Cardiovascular Events
Interventions: endothelial function testing; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Microalbuminuria
Interventions: benazepril; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peripheral Arterial Disease
Interventions: Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Peripheral Arterial Disease
Interventions: Pro-Omega, ProOmega Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Covid19-associated ARDS, Covid19, ARDS
Interventions: AV-001, Placebo; Drug · Other
Lead sponsor: Vasomune Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardioprotection
Interventions: Chocolate; Other
Lead sponsor: Griffin Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Diseases, Metabolic, Insulin Sensitivity
Interventions: Intralipid, ClinOleic, Dextrose, Saline (control); Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Macular Edema
Interventions: KVD001 Injection, Sham Procedure; Drug · Other
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more

Conditions: Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: NEO40 Daily; Dietary Supplement
Lead sponsor: Hypertension Institute, Nashville; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced Lung Cancer
Interventions: BNT324, BNT327; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 17
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more

Conditions: Coronary Artery Disease (CAD)
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: Active breakfast, Control breakfast; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 55 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pre-Eclampsia
Interventions: Acetylsalicylic Acid 81 mg, Acetylsalicylic Acid 162 mg, Control; Drug · Other
Lead sponsor: John O'Brien, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Trauma, PTSD, Endothelial Dysfunction
Interventions: Psychophysiological fear conditioning and extinction task, Eyetracking task; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction, LVAD
Interventions: Exposure of interest - Use of left ventricular assist device (LVAD); Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Healthy, Hypercholesterolemia, Hypertension
Interventions: investigate the relationship between in vivo and in vitro vascular responses; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Disease, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infection, Cardiovascular Disease, Inflammation
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 80 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Complement and Cardiovascular Risk in Adolescents

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

Molecular Mechanisms of Type 2 Diabetes Mellitus

Assessment of Endothelial Function, Apolipoproteins and Adiponectin

Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II

A First-in-Human Study of AV-001 in Healthy Subjects

Cocoa and Endothelial Function in Adults With Elevated BMI

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

Acute Berry Intake on Metabolic Control and Cognitive Function

Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia

Key Dimensions of PTSD and ED

Endothelial Function in Mechanical Circulatory Support

Study of the Response of Human Small Blood Vessels

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk